First patient dosed in registrational clinical trial of mesutoclax for the treatment of BTKi-experienced mantle cell lymphoma in China
Dr. Cui Jisong, co-founder, chairman and CEO of InnoCare Pharma, said: “Mesutoclax, as an important asset in the field of hematological malignancies, has the potential to bring new treatment hope to lymphoma patients. We will continue to accelerate the clinical development of mesutoclax to provide more effective treatment options for patients in China and around the world.”
Share:
More News
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.
“Many solid tumors remain difficult to treat despite advances in immunotherapy,” said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. “Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents.”
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that the first patient has been dosed in a Phase III clinical trial evaluating its novel Nectin-4-targeting ADC (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW2821) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).